Octreotide

What it's for

Octreotide is a synthetic 8–amino-acid peptide somatostatin analog available as short-acting injection, long-acting LAR (long-acting release), and oral capsules (Mycapssa) for selected indications. It reduces symptoms of carcinoid syndrome and VIPomas (rare VIP-secreting tumors), treats acromegaly in appropriate patients, and has other labeled specialty uses.

What it does for the body

It reduces symptoms of carcinoid syndrome and VIPomas (rare VIP-secreting tumors), treats acromegaly in appropriate patients, and has other labeled specialty uses. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.

What it targets

Somatostatin receptors (lock-and-key landing spots on cells) activating its target pathway suppresses pathologic hormone secretion (growth hormone, serotonin, VIP, etc.). Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.

Research context

Bottom line for readers: Octreotide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

• Digestive research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Octreotide — FDA.gov search
• ClinicalTrials.gov search: Octreotide — U.S. clinical trials registry
• Drugs@FDA search: Octreotide — FDA drug database (if approved)
• PubMed search: Octreotide — NCBI PubMed
• PubMed Central search: Octreotide — NCBI PMC

Reference

No ref on file.